This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Píndaro Martínez-Osuna, MD; Luis R. Espinoza, MD
Tampa, Fla

Arch Intern Med. 1991;151(6):1239.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In regard to an editorial¹ and two articles,^2,3 in the October 1990 issue of the ARCHIVES, as well as related literature on the matter,⁴ we would like to comment on our experience in the treatment of the eosinophilia-myalgia syndrome (EMS).

Since October 1989, we have seen 12 patients with EMS, ranging in age from 34 to 82 years, who developed the syndrome after 1 month to 12 years of tryptophan—containing product intake. In 11 patients, the most prominent manifestations were weight loss, fatigue, malaise, diffuse generalized myalgia with predominantly proximal weakness, and wasting, as well as numbness, paresthesia, a transient maculopapular rash, and scleroderma like changes of the face, trunk, limbs, and the esophagus. It is noteworthy to mention that seven patients developed a clinical picture indistinguishable from idiopathic progressive systemic sclerosis, as opposed to other reports.⁵ All but one, who developed a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?